ALERT: COVID19 Update: For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patient’s protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Telemedicine visits are available for routine office visits.

All Patients – Very Important: Regardless of vaccination status.  If you are experiencing a fever or cold-like like symptoms, which also include GI Symptoms and Diarrhea, you should contact your Virginia Cancer Specialists Advice Line before visiting our clinics for scheduled appointments. This includes symptoms of respiratory illness, such as coughing or difficulty breathing.  More Information-PLEASE CLICK HERE

Find A Clinical Trial

Disease Type: Lung

Trial ID APG1252SU101
Sponsor ID

A Multi-Center, Phase I/II Study of Combination APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer

Principal Investigator
Alexander I Spira, MD, PhD, FACP
1 Location
Trial ID U31402-A-U201
Sponsor ID HERTHENA-Lung01

A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects With Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Principal Investigator
Alexander I Spira, MD, PhD, FACP
1 Location
Trial ID DS1062-A-U301
Sponsor ID TROPION-Lung01

Phase 3 Randomized Study of DS-1062A Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations

Principal Investigator
Alexander I Spira, MD, PhD, FACP
1 Location
Trial ID DS1062-A-U202
Sponsor ID TROPION-Lung05

Phase 2, Single-arm, Open-label Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations and Progressed on or After Kinase Inhibitor Therapy and Platinum Based Chemotherapy

Principal Investigator
Alexander I Spira, MD, PhD, FACP
1 Location
Trial ID 20381
Sponsor ID MYLUNG Part 2

Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)

Principal Investigator
Alexander I Spira, MD, PhD, FACP
5 Locations
Trial ID 20331
Sponsor ID VS-6766-202

A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) Non-Small Cell Lung Cancer (NSCLC)

Principal Investigator
Alexander I Spira, MD, PhD, FACP
5 Locations
Trial ID 19239
Sponsor ID CX-839-014 "KEAPSAKE"

CX-839-014 “KEAPSAKE”: A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)

Principal Investigator
Alexander I Spira, MD, PhD, FACP
1 Location
Trial ID 20249
Sponsor ID 61186372NSC3001

A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Principal Investigator
Alexander I Spira, MD, PhD, FACP
5 Locations
Trial ID CLN-081-001
Sponsor ID CLN-081-001

A Phase 1/2a, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Principal Investigator
Alexander I Spira, MD, PhD, FACP
1 Location
Trial ID 73841937NSC1001
Sponsor ID Janssen

An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer

Principal Investigator
Alexander I Spira, MD, PhD, FACP
1 Location